JAMA Network highlights trial evidence that intensive LDL-C lowering with evolocumab plus statin reduced first major cardiovascular events in people with diabetes without known significant atherosclerosis, reinforcing aggressive prevention strategies.
Evolocumab for Heart Protection in People With Diabetes
intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event
VESALIUS-CV trial
Evolocumab for Heart Protection in People With Diabetes #shorts.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare